Safety & evidence

Why we publish
no doses

You will not find an amount, a schedule or a calculator for people anywhere on this site. That is a deliberate editorial rule, and here is the reasoning.

The 6AM mark rendered in glass
Short answerSafety & evidence · 6 min read · Updated 17 Nov 2026

6AM publishes no doses, protocols, cycles or dose calculators for any compound. Three reasons: a dose is medical advice about a specific person; most research peptides have no human dose-finding study, so nobody knows a right amount; and the FDA has treated dosing and preparation guidance on sellers’ websites as evidence of intended human use. We publish evidence, lab literacy and storage instead.

Key takeaways

  • No page, tool or guide on 6AM gives an amount, frequency, schedule, route or calculator for use in people or animals.
  • Finding a dose is the job of controlled human trials. For BPC-157, the FDA found only small, exploratory studies and no human pharmacokinetic data for most routes.
  • Animal doses do not convert into human doses. Even FDA's method for first-in-human trials treats the conversion as a cautious starting point inside a supervised study.
  • In August 2026 the FDA told several peptide sellers that “research use only” labels did not outweigh website content showing intended human use, including dosing text and a “peptide calculator.”
  • What we publish instead: graded evidence, how to read lab reports, storage and handling, and regulatory status.

01What we don't publish

  • Doses or amounts for people or animals, for any compound, approved or not.
  • Protocols, schedules, cycles or durations.
  • Dose calculators. Our tools check paperwork and convert mass units; none calculates or suggests an amount for use.
  • Routes or technique for use in a person.
  • Combinations. Evidence attaches to one compound at a time.

This is written into our editorial policy: human dosing, cycles and protocols are on the list of things we never publish. Anything that reads as dosing advice is removed before a page goes live.

02Reason 1: a dose is advice about a person

A dose only means something for a particular body: its weight, kidneys and liver, other medicines, conditions and goals. Choosing one, and watching what happens, is clinical work. We review research; we do not see patients, and we do not know you.

Most compounds in our library are research materials, not approved for use in people anywhere. Publishing amounts for them would put us in the position of advising on a use that no regulator has assessed. For approved medicines, the dose belongs to the prescriber and the label.

03Reason 2: what we don't know, human dose data

For most research peptides, there is no right amount to publish, because no one has done the work to find one.

Finding a dose takes controlled trials. Before the phase 2 trial of retatrutide (an investigational drug, not approved anywhere), the investigators wrote that its dose-response relationships for side effects, safety and efficacy “are not known.” They answered that question by randomising 338 adults across several arms and a placebo group for 48 weeks. Gastrointestinal side effects turned out to be dose-related.

Most research peptides have never had that kind of study:

  • BPC-157. FDA staff’s July 2026 review found five small human studies whose doses were “likely exploratory in nature,” and no human pharmacokinetic data after oral, subcutaneous, nasal or transdermal use. A 2026 orthopaedic review reached the same point: validated dosing, pharmacokinetic and long-term safety data are lacking.
  • TB-500. The FDA has identified no human exposure data at all.
  • Animal studies. They do not translate into human amounts. FDA guidance for first-in-human trials (2005) converts animal data into a human-equivalent figure, then divides it by a safety factor, generally at least 10, to set a cautious starting point for healthy volunteers inside a supervised study. Its stated purpose is “to ensure the safety of the human volunteers,” not to set a dose for use.

Numbers that circulate online for these compounds do not come from dose-finding trials. That is a gap in the evidence, and we would rather show the gap than fill it.

04Reason 3: regulators read dosing content as intended use

Under US rules, what a product is “intended” for is judged objectively. The FDA regulation (21 CFR 201.128) says intent may be shown by “labeling claims, advertising matter, or oral or written statements,” and by the circumstances in which a product is sold.

In warning letters dated 24 August 2026, the FDA applied this to peptide sellers. It wrote that despite “research use only” statements, “evidence obtained from your website establishes that your products are intended to be drugs for human use.” One letter quoted website text about once-weekly dosing, and cited a “peptide calculator” and a “peptide guide” which, with bacteriostatic water, “collectively provide the means to prepare an injectable drug for human administration.” Another cited bacteriostatic water sold alongside a “peptide calculator.”

The UK looks at presentation too. The MHRA assesses how a product is presented through labelling, packaging, advertising and websites when deciding whether it is a medicine.

More details: what “research use only” means.

05What we publish instead

The evidence

What was studied, in what model, with what result, graded from cell study to controlled trial. Start with evidence grades.

The lab bench

How to read a certificate of analysis, what HPLC and mass spectrometry measure, and how to store lyophilised material. See how to read a COA and peptide storage.

The rules

Where each compound stands with the FDA, MHRA, TGA and WADA, dated to the decision. See regulatory status.

Have a question about your own health? We can point you to what the research shows. For anything about your body, a doctor who knows you is the right call.

Plain-English summary of public sources, checked 17 November 2026. Not medical or legal advice. This content is educational and does not describe use in humans. If you have a health condition, consult a licensed clinician who knows you.

RefSources

  1. US Food and Drug Administration. Warning letter to Royal Peptides LLC, MARCS-CMS 734884. Warning letter, 24 August 2026. www.fda.gov/inspections-compliance-enforcement-and-criminal-…
  2. US Food and Drug Administration. Warning letter to NuScience Peptides LLC, MARCS-CMS 733652. Warning letter, 24 August 2026. www.fda.gov/inspections-compliance-enforcement-and-criminal-…
  3. US Food and Drug Administration. Warning letter to Peak Performance Peptides, MARCS-CMS 735127. Warning letter, 24 August 2026. www.fda.gov/inspections-compliance-enforcement-and-criminal-…
  4. Code of Federal Regulations. 21 CFR 201.128, Meaning of “intended uses”. eCFR, current text (86 FR 41401, 2021). www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-20…
  5. Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. GOV.UK guidance, updated 2 July 2026. www.gov.uk/guidance/borderline-products-how-to-tell-if-your-…
  6. US Food and Drug Administration. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Guidance for industry, July 2005. www.fda.gov/media/72309/download
  7. US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026. www.fda.gov/media/193343/download
  8. US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. FDA web page, content current as of 22 April 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  9. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med, 2023;389:514–526. PMID 37366315. pubmed.ncbi.nlm.nih.gov/37366315/
  10. Tham A, Hodgkins CW, Kennedy JG. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg, 2026 (online ahead of print). PMID 42937313. pubmed.ncbi.nlm.nih.gov/42937313/

Plain-English summary of public sources, not legal or medical advice. Last checked 17 Nov 2026.

Questions

Can you tell me how much BPC-157 people use?

No. We do not publish amounts for any compound, and for BPC-157 no human dose-finding study exists: the FDA found only small, exploratory studies. Figures circulating online do not come from dose-finding trials.

Why not publish a calculator, if it is only maths?

Because a calculator for amounts is guidance for use. In 2026 the FDA cited a “peptide calculator” offered alongside bacteriostatic water as part of the evidence that products were intended for human use. Our tools check paperwork and convert mass units only.

Can animal study doses be converted to a human dose?

Not for use. FDA's method for first-in-human trials converts animal data into a human-equivalent figure and divides it by a safety factor, generally at least 10, to set a cautious starting point for a supervised study. It is a safety procedure for trials, not a dose.

Do you publish doses for approved medicines?

No. For approved medicines, the dose is set by the prescriber and the official label, which is the right source.

Where should I go with a question about my own health?

To a doctor who knows you. We can point you to what the research shows, but we cannot advise on anyone's health.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page